Relay Therapeutics (RLAY) Non-Current Assets (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Non-Current Assets data on file, last reported at $41.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $41.2 million, down 31.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $178.6 million (down 29.96% YoY), and the FY2025 annual result was $43.1 million, down 30.66% from the prior year.
• Non-Current Assets eased to $41.2 million in Q1 2026 per RLAY's latest filing, from $43.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $81.4 million in Q3 2022 and troughed at $33.6 million in Q2 2022.
• A 5-year average of $61.2 million and a median of $65.0 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 151.64% in 2022, then plunged 31.07% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $80.3 million in 2022, then dropped by 7.96% to $73.9 million in 2023, then slipped by 15.95% to $62.1 million in 2024, then plunged by 30.66% to $43.1 million in 2025, then retreated by 4.42% to $41.2 million in 2026.
• Business Quant data shows RLAY's Non-Current Assets at $41.2 million in Q1 2026, $43.1 million in Q4 2025, and $46.0 million in Q3 2025.